Nanomerics Wins the United Kingdom King's Award for Enterprise Innovation 2024
Nanomerics Ltd., a private speciality pharmaceutical company today announced that it had been awarded the prestigious King's Award for Enterprise 2024 in the Innovation category. The King's Award for Enterprise is the most prestigious business award in the UK.
LONDON, UK / ACCESSWIRE / May 6, 2024 / The King's Award for Enterprise is the most prestigious business award in the UK. The award recognises exceptional achievements in business in one of four categories: Innovation, International Trade, Sustainable Development and Promoting Opportunity Through Social Mobility. Nanomerics' award recognises the company's innovative medicine technologies. Nanomerics Ltd. has developed an active excipient platform for Precision Medicines with improved efficacy and reduced side effects. This is achieved by encapsulating nano-scaled drug doses in a new Molecular Envelope Technology (MET), enabling water insoluble drug compounds to pass through mucosal barriers and more effectively reach the disease site. The novel polymer designs enable the encapsulation of ingredients in a much more stable form than has been achievable before, transforming a laboratory technique into a therapeutic solution. The platform has received a Medicines and Healthcare Products Regulatory Agency (MHRA) Innovation Passport, the entry point to the Innovative Licensing and Access Pathway (ILAP), which aims to accelerate time to market, facilitating patient access to innovative technologies.
Nanomerics' MET is a non-irritant ocular penetration enhancer that has been used to formulate eye drops such as: OC134, indicated for severe allergic eye disease and OC137, indicated for the treatment of retinal diseases. Nanomerics is currently executing an OC134 Phase I clinical trial project. The conclusion of trial will transform the company to a clinical stage company and enable Nanomerics' MET to be used for a variety of ophthalmic active pharmaceutical ingredients.
Nanomerics' MET also underpins a number of Nanomerics' central nervous system assets. Noteworthy among these is Envelta™, a nasal spray powder, which is being developed as a pain therapeutic. Envelta™ has been out-licensed by Nanomerics to Virpax Pharmaceuticals (VRPX). Envelta™ is being developed by Virpax Pharmaceuticals in collaboration with the US National Institutes of Health (NIH). Nanomerics also has other collaborations with companies aiming to develop new medicines using its MET.
Drug developers using Nanomerics' technologies benefit from extending the commercial life of drugs and creating new treatments. Patients benefit from less intrusive delivery methods, e.g. retina eye drops that avoid the need for needles and brain medicines that may be administered as nasal sprays. Ultimately these drug delivery technologies aim to minimise side effects and increase patient adherence to their medications. Nanomerics' technologies, by locating more of the drug molecule at disease sites, make medicines more efficacious and more likely to succeed in alleviating patient signs and symptoms.
Nanomerics is based in state of the art laboratories in North London. Nanomerics' Chief Executive Officer, Professor Andreas G. Schätzlein, says, "it is a real honour to win the King's Award for Enterprise 2024 in the Innovation category. This award recognises the efforts we are making to ensure that drug development has a higher likelihood of success. On behalf of the entire company, we express our thanks to the awarding committee."
About Nanomerics
Nanomerics Ltd is a speciality pharmaceutical company based in London, UK. Nanomerics was founded to commercialise its biocompatible polymer technologies for drug delivery and other applications. Nanomerics' proprietary technology is based on world leading know-how and scientific leadership in polymer nanotechnology. Nanomerics creates uniquely differentiated, patented pharmaceutical assets, underpinned by high quality science.? For example, the company's Molecular Envelope Technology (MET) is a unique patented biocompatible polymer that delivers a step change in target tissue bioavailability. The founding scientists, Professor Ijeoma F. Uchegbu and Professor Andreas G. Schätzlein developed the technology at the Universities of Strathclyde and Glasgow and, latterly at the UCL School of Pharmacy. Pharmaceutical product candidates in development include the eye drops: OC134 for the treatment of moderate to severe allergic conjunctivitis and OC137 for the treatment of retinal diseases. Additionally, a number of pharmaceutical product candidates have already been out-licensed by Nanomerics to Virpax Pharmaceuticals (NASDAQ:VRPX), e.g. Envelta™, which is being developed as a pain therapeutic and NobrXiol™, in development for the treatment of epilepsy. For more information please visit www.nanomerics.com
About the King's Award for Enterprise 2024
The King's Awards for Enterprise were previously known as The Queen's Awards for Enterprise and were renamed last year to reflect His Majesty The King's desire to continue the legacy of HM Queen Elizabeth II by recognising outstanding UK businesses. The Award programme, now in its 58th year, has awarded over 7,000 companies since its inception in 1965. This year's King's Awards for Enterprise are given for outstanding achievement in:
Innovation (59)
International trade (161)
Sustainable development (29)
Promoting opportunity through social mobility (8)
His Majesty's Lord Lieutenants will be presenting the Awards to businesses locally throughout the year. Eligible businesses are free to apply for one or more categories. The recipients pass a robust assessment process, judged by experts from industry, academia, the voluntary sector and senior officials in Whitehall. On that basis, each year, The King's Awards for Enterprise recipients are recommended by the Prime Minister.
The full list of Awardees across the four categories can be found?in the London Gazette:?https://www.thegazette.co.uk/awards-and-accreditation/content/kings-awards-for-enterprise-2024
For more information please visit www.nanomerics.com
Or contact:
Name: Pedro Margarido
Company: Nanomerics Ltd
Email: [email protected]
Contact: +44 2045585366
SOURCE: Nanomerics Ltd
View the original press release on accesswire.com
News published on and distributed by:
